Can patient reporting affect radiation pneumonitis?

ONCOLOGY

Volumn 22, Issue 1, 2008, Pages 52-53

  Movsas, Benjamin ^a   Chetty, Indrin ^a   Ajlouni, Munther ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE;

CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; DOSIMETRY; HUMAN; LUNG FUNCTION TEST; LUNG NON SMALL CELL CANCER; MULTIVARIATE ANALYSIS; NOTE; PHYSICAL PARAMETERS; RADIATION DOSE; RADIATION PNEUMONIA;

EID: 38949185370     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (8)

1. Movsas B, Swann S, Curran W. Sociodemographic factors are significant predictors of toxicity in RTOG non-Operative NSCLC trials. Int J Radiat Oncol Biol Phys 66(3):S62, 2006.
2. Konski A, Pajak T, Movsas B, et al: Disadvantage of men living alone participating in Radiation Therapy Oncology Group head and neck trials. J Clin Oncol 24:4177-4183, 2006.
3. Movsas B, Scott C, Langer C, et al: Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation therapy oncology group trial 98-01. J Clin Oncol 23:2145-2154, 2005.
4. Komaki R, Lee JS, Kaplan B, et al: Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: Preliminary results. Semin Radiat Oncol 12(1 suppl 1):46-49, 2002.
5. Trotti A, Pajak T, Gwede C, et al: TAME: Development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol 8:613-624, 2007.
6. Jin J, Ajlouni M, Chen Q, et al: Quantification of incidental dose to potential clinical target volume (CTV) under different stereotactic body radiation therapy (SBRT) techniques for non-small cell lung cancer: Tumor motion and using internal target volume (ITV) could improve dose distribution in CTV. Radiother Oncol Sept 28, 2007 [epub ahead of print].
7. Timmerman R, McGarry R, Yiannoutsos C, et al: Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24:4833-4839, 2006.
8. Movsas B, Patel A, Ajlouni M, et al: Is it safe to treat central lung lesions with SBRT? Presented at the American Society of Therapeutic Radiology (ASTRO) Presidential Session, October 2007.